List of Zurampic drug patents

Zurampic is owned by Ironwood Pharms Inc.

Zurampic contains Lesinurad.

Zurampic has a total of 9 drug patents out of which 0 drug patents have expired.

Zurampic was authorised for market use on 22 December, 2015.

Zurampic is available in tablet;oral dosage forms.

Zurampic can be used as reduction of serum uric acid levels; treatment of hyperuricemia; treatment of gout, achieving a therapeutic benefit in a subject with gout; treatment of gout, treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone, coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; below 6mg/dl in patients having uric acid deposits; and/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%, reduction of serum uric acid levels, treatment of hyperuricemia.

The generics of Zurampic are possible to be released after 29 February, 2032.

Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(2 years from now)

US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(5 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(5 years from now)

US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(6 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(6 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(6 years from now)

US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(8 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(8 years from now)

Drugs and Companies using LESINURAD ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Achieving a therapeutic benefit in a subject with gout; Treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of hyperuricemia; Reduction of serum uric acid levels; Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; Below 6mg/dl in patients having uric acid deposits; And/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%

Dosage: TABLET;ORAL

More Information on Dosage

ZURAMPIC family patents

62

United States

13

European Union

11

Japan

9

China

7

Korea, Republic of

7

Australia

7

South Africa

7

EA

7

New Zealand

6

Brazil

6

Canada

5

Spain

5

Israel

5

Mexico

4

Hong Kong

4

RS

4

Poland

4

Lithuania

4

Ukraine

4

Cyprus

4

Slovenia

4

Hungary

4

Portugal

4

Singapore

4

Croatia

4

Taiwan, Province of China

4

Denmark

3

Argentina

3

ME

2

Austria

2

Chile

2

Malaysia

2

Luxembourg

2

Norway

2

Ecuador

1

Morocco

1

Netherlands

1

Tunisia

1

Colombia

1

Turkey

1

India

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in